Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.
about
Mitochondrial disorders in children: toward development of small-molecule treatment strategiesFunctional and Gait Assessment in Children and Adolescents Affected by Friedreich's Ataxia: A One-Year Longitudinal StudyDevelopment of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxiaCommon data elements for clinical research in Friedreich's ataxia.Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia.Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.Clinical data and characterization of the liver conditional mouse model exclude neoplasia as a non-neurological manifestation associated with Friedreich's ataxia.A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxiaQuantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease).Ophthalmic features of Friedreich ataxia.Frataxin levels in peripheral tissue in Friedreich ataxia.Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participantsProgression of Friedreich ataxia: quantitative characterization over 5 yearsHigh-throughput immunoassay for the biochemical diagnosis of Friedreich ataxia in dried blood spots and whole blood.Degenerative Ataxias: challenges in clinical research.Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials.A review of Friedreich ataxia clinical trial results.Clinical features of Friedreich's ataxia: classical and atypical phenotypes.Systematic review of the psychometric properties of balance measures for cerebellar ataxia.Anaesthesia for a patient with Friedreich's ataxiaPharmacological therapeutics in Friedreich ataxia: the present state.Annual change in Friedreich's ataxia evaluated by the Scale for the Assessment and Rating of Ataxia (SARA) is independent of disease severity.Impact of diabetes in the Friedreich ataxia clinical outcome measures study.Longitudinal strain in Friedreich Ataxia: a potential marker for early left ventricular dysfunction.Analysis of the visual system in Friedreich ataxia.Therapeutic interventions in the primary hereditary ataxias.Open-label pilot study of interferon gamma-1b in Friedreich ataxia.How does performance of the Friedreich Ataxia Functional Composite compare to rating scales?A study of up to 12 years of follow-up of Friedreich ataxia utilising four measurement tools.Emerging therapeutics for the treatment of Friedreich’s ataxiaLongitudinal analysis of contrast acuity in Friedreich ataxiaAn open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels
P2860
Q26767327-EDDF4A0C-544E-48CE-A31E-D034FB805EE5Q27323220-9D0DCA9D-DB72-490F-A984-8774A356DE9BQ28488251-85A4EEE4-E7FC-4847-B28D-69DCA5BD7875Q30581588-C310CEBB-D877-4ABB-A25F-F22E4584B860Q30602174-C56F56A4-FA25-46C3-9D74-7B0B1A96684DQ33968480-CDA9CD78-A9DE-49B8-96E2-A0EC8707D9CAQ34317949-D543AF00-D9A7-4BC0-9BB5-F37100B0BDBEQ34376985-C3D3EB70-73C7-40CC-A9D9-3952DB5545A7Q35599514-A5EBF23C-9742-4433-97BE-DE311E09B42DQ35737384-4791971B-1291-4DDD-B707-97F17BEB3EF0Q36010435-17D1CB67-4C51-4CF7-86B6-251F03CDCF9EQ36907355-04E88DFE-78AD-428B-B5D1-207B5F0CBB53Q37247066-642846F5-D377-48BE-BAEB-E71577E1BA26Q37557229-C5BB9335-BA83-4A5C-889F-3C04E7776109Q37572929-16A85A1D-DD57-447F-8CFA-CE9488EFACE1Q37941519-020C8AFA-F4B8-4254-95B8-9261858AC118Q38038592-E9EBDF8B-AA08-4B69-A857-FEAA20C6249AQ38121948-099DB86C-EF68-446F-9416-A40E3D3AE38BQ38219382-287D86E6-F299-4A39-9F43-2DEE87FD43BBQ38671034-E6CA4FA5-D3F7-4EC3-A790-2BFF0BAFF2ACQ39445743-2B1F077D-C73C-4FA8-AD22-A8AA708EE8BCQ39687901-6185BD95-269D-4A4A-8937-58A4FC53C8B5Q41509984-6352E5EB-C587-47E9-8318-822EB17B1591Q43842780-B5FD26D0-3ACA-4CB6-9A0B-BB8444E6E95FQ45809518-04FAE275-2230-45DB-816D-862EEFA7239BQ48340750-1BE1FA53-EEB8-469B-A4AC-01683EF98073Q50458074-AE38F361-24E8-4CCE-8CDF-4C7ABAC550D7Q50536618-B4814CA4-6095-4531-8CC8-70BADD6A27E8Q53085760-51C8DA2A-4599-4E81-9C79-C8D5447AC615Q56700247-7803D5E2-0D0F-4A44-A58A-E0494F18E018Q57175092-B0C2AD3E-8F5F-40D9-BF43-00B051BFEAADQ57905710-EE04112C-CEB3-4A3A-A4D1-888BB44CB933
P2860
Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Measuring the rate of progress ...... ons for clinical trial design.
@ast
Measuring the rate of progress ...... ons for clinical trial design.
@en
Measuring the rate of progress ...... ons for clinical trial design.
@nl
type
label
Measuring the rate of progress ...... ons for clinical trial design.
@ast
Measuring the rate of progress ...... ons for clinical trial design.
@en
Measuring the rate of progress ...... ons for clinical trial design.
@nl
prefLabel
Measuring the rate of progress ...... ons for clinical trial design.
@ast
Measuring the rate of progress ...... ons for clinical trial design.
@en
Measuring the rate of progress ...... ons for clinical trial design.
@nl
P2093
P2860
P356
P1433
P1476
Measuring the rate of progress ...... ons for clinical trial design.
@en
P2093
Christopher M Gomez
David R Lynch
George Wilmot
Jennifer M Farmer
Khalaf O Bushara
Lisa S Friedman
Robert B Wilson
S H Subramony
Susan Perlman
Tetsuo Ashizawa
P2860
P304
P356
10.1002/MDS.22912
P407
P577
2010-03-01T00:00:00Z